FDA Asks for More Preclinical Data on XenoPort, Inc. RLS Drug

Reuters -- XenoPort Inc said U.S. health regulators have asked the company to submit additional preclinical data on its key drug for restless leg syndrome, and no new clinical trials are expected at this time.

MORE ON THIS TOPIC